Abstract | OBJECTIVE: METHODS: We used 2 population-based studies (ParkWest, Norway, and Parkinson's Environment and Gene, USA) providing us with 399 patients with PD with European ancestry and a PD diagnosis after age 55 years to assess the associations between 4 PRSs and hallucinations after 5 years of mean disease duration. Based on the existing genome-wide association study of other large consortia, 4 PRSs were created: one each using AD, SZ, and PD cohorts and another PRS for height, which served as a negative control. RESULTS: A higher prevalence of hallucinations was observed with each SD increase of the AD-PRS (odds ratio [OR]: 1.37, 95% confidence interval [CI]: 1.03-1.83). This effect was mainly driven by APOE (OR: 1.92, 95% CI: 1.14-3.22). In addition, a suggestive decrease and increase, respectively, in hallucination prevalence were observed with the SZ-PRS and the PD-PRS (OR: 0.77, 95% CI: 0.59-1.01; and OR: 1.29, 95% CI: 0.95-1.76, respectively). No association was observed with the height PRS. CONCLUSIONS: These results suggest that mechanisms for hallucinations in PD may in part be driven by the same genetic architecture that leads to cognitive decline in AD, especially by APOE.
|
Authors | Cynthia D J Kusters, Kimberly C Paul, Aline Duarte Folle, Adrienne M Keener, Jeff M Bronstein, Valerija Dobricic, Ole-Bjørn Tysnes, Lars Bertram, Guido Alves, Janet S Sinsheimer, Christina M Lill, Jodi Maple-Grødem, Beate R Ritz |
Journal | Neurology. Genetics
(Neurol Genet)
Vol. 6
Issue 5
Pg. e492
(Oct 2020)
ISSN: 2376-7839 [Print] United States |
PMID | 32802953
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. |